Efficacy and Safety Study of TOOKAD® Soluble for Localised Prostate Cancer Compared to Active Surveillance. (PCM301)

Share this content:
Efficacy and Safety Study of TOOKAD® Soluble for Localised Prostate Cancer Compared to Active Surveillance. (PCM301)

Sponsor and Collaborators
Steba Biotech S.A.

Contact
Abdel Rahmene AZZOUZI, Professor
+ 33 (0) 2 41 35 35 18
ARAzzouzi@chu-angers.fr

Mark Emberton, Professor
+ 44 (0) 20 7679 9372
markemberton1@btinternet.com

Principal Investigator
Mark Emberton, Professor
University College of London Hospital , United Kingdom

ClinicalTrials.gov Identifier
NCT01310894
You must be a registered member of Renal and Urology News to post a comment.

Sign Up for Free e-newsletters